Ambrosia Biosciences Inc. logo

Ambrosia Biosciences Inc.

Small molecule therapies for obesity and metabolic disorders, delivered orally

38 employees · est. 2024 · Boulder, United States

VS
Lumen Bioscience logo

Lumen Bioscience

Our patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.

90 employees · est. 2017 · Seattle, United States

Lumen Bioscience is the older company (2024 vs 2017); Lumen Bioscience is the larger of the two.

Side-by-Side Comparison

Ambrosia Biosciences Inc. Lumen Bioscience
Founded
2024 2017 older
Headquarters
Boulder, United States Seattle, United States
Employees
38 90 larger
Industry
Biotechnology, Pharmaceutical Biopharma, Biotechnology, Life Sciences
Funding Stage
Series B Grant
Total Funding
$125.00M $66.95M
Funding Rounds
3 9
Services
Development of small molecule-based therapies, Drug discovery using structure-based approaches, Rapid iteration from initial discovery to IND filings, Discovery of orally delivered therapies for obesity Not tracked yet
Target Customers
Biotechnology investors, Pharmaceutical industry partners, Patients with obesity and metabolic disorders, Scientific community focusing on metabolic and cardiometabolic conditions Not tracked yet
Taxonomy
Small Molecule Therapies, Obesity Treatment, Metabolic Disorders, Drug Discovery, Orally Delivered Drugs, GLP-1, Incretin Hormones, Class B GPCRs, Therapeutics Development, Pharmaceutical Innovation, Novel Drug Compounds Therapeutic Proteins, Clinical-Stage, Oral Antibody Therapeutics, Topically Delivered Drugs, Mucosally Delivered Drugs, Industrial Biotechnology, Cyanobacteria, Pigments, Animal Health
Website
ambrosiabiosciences.com lumen.bio
Ambrosia Biosciences Inc. logo

About Ambrosia Biosciences Inc.

Ambrosia Biosciences Inc., founded in 2024, is positioned at the forefront of tackling global health challenges in Biotechnology and Pharmaceutical industries. The company is pioneering the development of orally delivered, small molecule-based therapies to address pressing issues such as obesity and...

Lumen Bioscience logo

About Lumen Bioscience

Lumen Bioscience, founded in 2017, is a biopharmaceutical and biotechnology company based in the United States. The company's patented technology harnesses the potential of the renowned food algae spirulina to develop oral antibody therapeutics. This innovative approach has garnered attention and su...

We will tell you when either one moves

BounceWatch watches Ambrosia Biosciences Inc. and Lumen Bioscience for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Ambrosia Biosciences I... and Lumen Bioscience — by email.

Frequently Asked Questions

Ambrosia Biosciences Inc. — Small molecule therapies for obesity and metabolic disorders, delivered orally. Lumen Bioscience — Our patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Ambrosia Biosciences Inc. has raised $125.00M while Lumen Bioscience has raised $66.95M.
Ambrosia Biosciences Inc. and Lumen Bioscience operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Ambrosia Biosciences Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Ambrosia Biosciences Inc. on 9 Jun 2026, and Lumen Bioscience on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy